Research Article
Formulation and In Vitro Evaluation of Bilayer Tablets of Nebivolol Hydrochloride and Nateglinide for the Treatment of Diabetes and Hypertension
Table 15
In vitro drug release data of Nateglinide sustained release tablets (N1 to N13).
| Time (hrs) | N1 | N2 | N3 | N4 | N5 | N6 | N7 | N8 | N9 | N10 | N11 | N12 | N13 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 18 ± 3.99 | 14 ± 3.45 | 16 ± 3.51 | 29 ± 3.68 | 19 ± 4.03 | 16 ± 4.02 | 15 ± 3.38 | 10 ± 3.37 | 9 ± 3.90 | 8 ± 3.25 | 12 ± 3.64 | 10 ± 3.31 | 10 ± 3.96 | 2 | 40 ± 3.46 | 38 ± 4.14 | 28 ± 4.07 | 38 ± 3.72 | 39 ± 3.72 | 32 ± 3.61 | 20 ± 3.64 | 18 ± 3.99 | 15 ± 3.68 | 13 ± 3.63 | 20 ± 3.36 | 18 ± 3.61 | 17 ± 3.64 | 3 | 56 ± 3.14 | 59 ± 3.78 | 49 ± 3.54 | 54 ± 3.58 | 48 ± 3.80 | 41 ± 3.94 | 31 ± 437 | 26 ± 3.42 | 26 ± 3.42 | 24 ± 4.01 | 31 ± 4.24 | 29 ± 3.64 | 30 ± 3.76 | 4 | 78 ± 4.44 | 72 ± 3.45 | 61 ± 3.92 | 79 ± 4.45 | 61 ± 4.19 | 59 ± 4.55 | 42 ± 4.11 | 37 ± 3.98 | 32 ± 4.20 | 30 ± 4.25 | 39 ± 3.81 | 37 ± 4.29 | 38 ± 3.22 | 5 | 85 ± 3.83 | 83 ± 4.42 | 75 ± 3.96 | 94 ± 3.83 | 80 ± 3.27 | 73 ± 3.93 | 53 ± 3.67 | 48 ± 3.71 | 39 ± 3.63 | 37 ± 3.45 | 47 ± 3.53 | 45 ± 4.23 | 47 ± 3.61 | 6 | 97 ± 4.56 | 90 ± 4.28 | 84 ± 3.52 | | 95 ± 3.36 | 85 ± 4.19 | 61 ± 4.10 | 59 ± 4.45 | 47 ± 3.06 | 45 ± 3.23 | 54 ± 3.69 | 53 ± 3.98 | 54 ± 3.83 | 7 | | 95 ± 4.01 | 90 ± 4.08 | | | 91 ± 3.40 | 69 ± 3.36 | 65 ± 3.23 | 53 ± 3.67 | 51 ± 3.64 | 62 ± 3.58 | 59 ± 3.87 | 60 ± 4.09 | 8 | | | 96 ± 3.81 | | | 98 ± 3.79 | 78 ± 3.44 | 78 ± 3.44 | 60 ± 3.27 | 58 ± 4.21 | 79 ± 4.34 | 70 ± 4.01 | 71 ± 3.56 | 9 | | | | | | | 97 ± 3.43 | 85 ± 3.87 | 75 ± 4.14 | 65 ± 3.82 | 88 ± 3.46 | 81 ± 3.97 | 82 ± 4.13 | 10 | | | | | | | | 98 ± 3.30 | 81 ± 3.74 | 74 ± 4.30 | 98 ± 3.97 | 90 ± 3.64 | 96 ± 3.98 | 11 | | | | | | | | | 92 ± 3.48 | 80 ± 4.16 | | 99 ± 4.15 | | 12 | | | | | | | | | 96 ± 3.92 | 89 ± 4.43 | | | |
|
|